Predictors of occult metastasis in clinical stage I nonseminoma: A systematic review

Journal of Clinical Oncology

Volumn 21, Issue 22, 2003, Pages 4092-4099

  Vergouwe, Yvonne ^a   Steyerberg, Ewout W ^a   Eijkemans, Marinus J C ^a   Albers, Peter ^a   Habbema, J Dik F ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY KI 67; ANTINUCLEAR ANTIBODY; MIB 1 ANTIBODY; MIB-1 ANTIBODY; MONOCLONAL ANTIBODY; TUMOR MARKER;

CANCER INVASION; CANCER RISK; CELL PROLIFERATION; CLINICAL TRIAL; CYTOPATHOLOGY; EMBRYONAL CARCINOMA; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; META ANALYSIS; NON SEMINOMATOUS GERMINOMA; OCCULT CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; TUMOR CELL; TUMOR VOLUME; ADULT; ARTICLE; CANCER STAGING; CHEMISTRY; GERM CELL TUMOR; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; METASTASIS; RISK FACTOR; TESTIS TUMOR;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; GERMINOMA; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0642286279     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.01.094     Document Type: Review

References (67)

1. Donohue JP, Thornhill JA, Foster RS, et al: Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): Modifications of technique and impact on ejaculation. J Urol 149:237-243, 1993
2. Pizzocaro G, Zanoni F, Salvioni R, et al: Surveillance or lymph node dissection in clinical stage I non-seminomatous germinal testis cancer? Br J Urol 57:759-762, 1985
3. Peckham MJ, Brada M: Surveillance following orchidectomy for stage I testicular cancer. Int J Androl 10:247-254, 1987
4. Bosl GJ, Motzer RJ: Testicular germ-cell cancer. N Engl J Med 337:242-253, 1997
5. Gelderman WAH, Schraffordt Koops H, Sleifer DTh, et al: Orchidectomy alone in stage I nonseminomatous testicular germ cell tumors. Cancer 59:578-580, 1987
6. Sturgeon JFG, Jewett MAS, Alison RE, et al: Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumor. J Clin Oncol 10:564-568, 1992
7. Baniel J, Foster RS, Rowland RG, et al: Complications of primary retroperitoneal lymph node dissection. J Urol 152:424-427, 1994
8. Meinardi MT, Gietema JA, van der Graaf WT, et al: Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18:1725-1732, 2000
9. Kollmansberger C, Hartmann JT, Kanz L, et al: Therapy-related malignancies following treatment of germ cell cancer. Int J Cancer 83:860-863, 1999
10. Sandeman TF, Yang C: Results of adjuvant chemotherapy for low-stage nonseminomatous germ cell tumors of the testis with vascular invasion. Cancer 62:1471-1475, 1988
11. Pont J, Höltl W, Kosak D, et al: Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: A prospective trial. J Clin Oncol 8:16-20, 1990
12. Raghavan D, Peckham MJ, Heyderman E, et al: Prognostic factors in clinical stage I non-seminomatous germ-cell tumours of the testis. Br J Cancer 45:167-173, 1982
13. Fujime M, Chang H, Lin C-W, et al: Correlation of vascular invasion and metastasis in germ cell tumors of testis: A preliminary report. J Urol 131:1237-1241, 1984
14. Moriyama N, Daly JJ, Keating MA, et al: Vascular invasion as a prognosticator of metastatic disease in nonseminomatous germ cell tumors of the testis. Cancer 56:2492-2498, 1985
15. Javadpour N, Young JDJ: Prognostic factors in nonseminomatous testicular cancer. J Urol 135:497-499, 1986
16. Hoskin P, Dilly S, Easton D, et al: Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: Implications for adjuvant chemotherapy. J Clin Oncol 4:1031-1036, 1986
17. Freedman LS, Parkinson MC, Jones WG, et al: Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 8554:294-298, 1987
18. Hoeltl W, Kosak D, Pont J, et al: Testicular cancer: Prognostic implications of vascular invasion. J Urol 137:683-685, 1987
19. Dunphy CH, Ayala AG, Swanson DA, et al: Clinical stage I nonseminomatous and mixed germ cell tumors of the testis. Cancer 62:1202-1206, 1988
20. Fung CY, Kalish LA, Brodsky GL, et al: Stage I nonseminomatous germ cell testicular tumor: Prediction of metastatic potential by primary histopathology. J Clin Oncol 6:1467-1473, 1988
21. Sogani PC, Fair WR: Surveillance alone in the treatment of clinical stage I nonseminomatous germ cell tumor of the testis (NSGCT). Semin Urol 6:53-56, 1988
22. Thompson PI, Nixon J, Harvey VJ: Disease relapse in patients with stage I nonseminomatous germ cell tumor of the testis on active surveillance. J Clin Oncol 6:1597-1603, 1988
23. Costello AJ, Mortensen PH, Stillwell RG: Prognostic indicators for failure of surveillance management of stage I non-seminomatous germ cell tumours. Aust N Z J Surg 59:119-122, 1989
24. Wishnow KI, Dunphy CH, Johnson DE, et al: Identifying patients with low-risk clinical stage I nonseminomatous testicular tumors who should be treated by surveillance. Urology 34:339-343, 1989
25. Jacobsen KG, Rorth M, Østerlind M, et al: Histopathological features in stage I non-seminomatous testicular germ cell tumours correlated to relapse. APMIS 98:377-382, 1990
26. Klepp O, Olsson AM, Henrikson H, et al: Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: Multivariate analysis of a prospective multicenter study. J Clin Oncol 8:509-518, 1990
27. Allhoff EP, Liedke S, Wittekind C, et al: DNA-content in NSGCT/CS I: A new prognosticator for biologic behaviour. J Cancer Res Clin Oncol 116:592, 1990
28. Rørth M, Jacobsen KG, von der Maasse H, et al: Surveillance alone versus radiotherapy after orchidectomy for clinical stage I nonseminomatous testicular cancer. J Clin Oncol 9:1543-1548, 1991
29. Colls BM, Harvey VJ, Skelton L, et al: Results of the surveillance policy of stage I non-seminomatous germ cell testicular tumours. Br J Urol 70:423-428, 1992
30. Sesterhenn IA, Weiss RB, Mostofi FK, et al: Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: A report from the testicular cancer intergroup study. J Clin Oncol 10:69-78, 1992
31. Austenfeld MS, Bilhartz DL, Nativ O, et al: Flow cytometric DNA ploidy pattern for predicting metastasis of clinical stage I nonseminomatous germ cell testicular tumors. Urology 41:379-383, 1993
32. Ondruš D, Hornak M: Orchiectomy alone for clinical stage I nonseminomatous germ cell tumors of the testis (NSGCT): A minimum follow-up period of 5 years. Tumori 80:362-364, 1994
33. Gels ME, Hoekstra HJ, Sleijfer DT, et al: Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: A single center 10-year experience. J Clin Oncol 13:1188-1194, 1995
34. de Riese WTW, de Riese C, Ulbright TM, et al: Flow-cytometric and quantitative histologic parameters as prognostic indicators for occult retroperitoneal disease in clinical-stage-I non-seminomatous testicular germ-cell tumors. Int J Cancer 57:628-633, 1994
35. Albers P, Bierhoff E, Neu D, et al: MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis. Cancer 79:1710-1716, 1997
36. Oliver RTD, Raja MA, Ong J, et al: Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage I malignant teratoma on overall relapse rate of stage 1 cancer patients. J Urol 148:1453-1456, 1992
37. Glasziou P, Irwig L, Bain C, et al: Systematic Reviews in Health Care. Cambridge, United Kingdom, Cambridge University Press, 2001
38. Peckham MJ, Barrett A, Husband JE, et al: Orchidectomy alone in testicular stage I non-seminomatous germ-cell tumours. Lancet 8300:678-680, 1982
39. Albers P, Siener R, Hartmann M, et al: Risk factors for relapse in stage I non-seminomatous germ-cell tumors: Preliminary results of the german multicenter trial. Int J Cancer 83:828-830, 1999
40. Mostofi FK, Sobin LH: Histological Typing of Testis Tumours. Geneva, Switzerland, World Health Organisation, 1977
41. Pugh RCB, Cameron KM: Teratoma, in Pugh R (ed): Pathology of the Testis. Oxford, United Kingdom, Blackwell, 1976, pp. 199-244
42. Harmer MH: TNM Classification of Malignant Tumours. Geneva, Switzerland, Union Internationale Centre le Cancer, 1978
43. Read G, Stenning SP, Cullen MH, et al: Medical research council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 10:1762-1768, 1992
44. Cattoretti G, Becker MHG, Key G, et al: Monoclonal antibodies against recombinant parts of Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168:357-363, 1992
45. Hardy RJ, Thompson SG: A likelihood approach to meta-analysis with random effects. Slat Med 16:619-629, 1996
46. Greenland S: Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 9:1-30, 1987
47. Moul JW, McCarthy WF, Fernandez EB, et al: Percentage of embryonal carcinoma and vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer. Cancer Res 54:362-364, 1994
48. Sosnowski M, Jeromin L, Pluzanska A: Is modified retroperitoneal lymph node dissection (MRLND) still feasible in the treatment of patients with clinical stage I non-seminomatous testicular cancer? Int Urol Nephrol 26:471-477, 1994
49. Albers P, Miller GA, Orazi A, et al: Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage A nonseminomatous testicular germ cell tumor at low risk for occult metastasis. Cancer 75:844-850, 1995
50. Nicolai N, Pizzocaro G: A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year follow up. J Urol 154:1045-1049, 1995
51. Sogani PC, Perrotti M, Herr HW, et al: Clinical stage I testis cancer: Long-term outcome of patients on surveillance. J Urol 159:855-858, 1998
52. Roeleveld TA, Horenblas S, Meinhardt W, et al: Surveillance can be the standard of care for stage I nonseminomatous testicular tumors and even high risk patients. J Urol 166:2166-2170, 2001
53. Alexandre J, Fizazi K, Mahé C, et al: Stage I non-seminomatous germ-cell tumours of the testis: Identification of a subgroup of patients with a very low risk of relapse. Eur J Cancer 37:576-582, 2001
54. Heidenreich A, Sesterhenn IA, Mostofi FK, et al: Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 83:1002-1011, 1998
55. Albers P, Ulbright TM, Albers J, et al: Tumor proliferative activity is predictive of pathological stage in clinical stage A nonseminomatous testicular germ cell tumors. J Urol 155:579-586, 1996
56. Klepp O, Dahl O, Flodgren P, et al: Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer. Eur J Cancer 33:1038-1044, 1997
57. Leibovitch I, Foster RS, Kopecky KK, et al: Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol 154:1759-1763, 1995
58. Pont J, Albrecht W, Postner G, et al: Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: Long-term results of a prospective trial. J Clin Oncol 14:441-448, 1996
59. Cullen MH, Stenning SP, Parkinson MC, et al: Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: A medical research council report. J Clin Oncol 14:1106-1113, 1996
60. Ondruš D, Matoska J, Belan V, et al: Prognostic factors in clinical stage I nonseminomatous gem cell testicular tumors: Rationale for different risk-adapted treatment. Eur Urol 33:562-566, 1998
61. Böhlen D, Borner M, Sonntag RW, et al: Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 161:1148-1152, 1999
62. Simon R, Altman DG: Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69:979-985, 1994
63. Altman DG, Lausen B, Sauerbrei W, et al: Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86:829-835, 1994
64. Merkel D, Dresseler L, McGuire WL: Flow cytometry, cellular DNA content, and prognosis in human malignancy. J Clin Oncol 5:1690-1703, 1987
65. Clark GM, Mathieu M-C, Owens MA, et al: Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 10:428-432, 1992
66. Fernandez EB, Sesterhenn IA, McCarthy WF, et al: Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. J Urol 152:1133-1138, 1994
67. Albers P, Siener R, Kliesch S, et al: Risk factors for relapse in clinical stage I non-seminomatous testicular germ cell tumors (NSGCT): Results of the German Testicular Cancer Study Group (GTCSG) trial. J Clin Oncol (in press)